# Reviewer DVUB — Score: 2 (Reject)
**Confidence: 4 (High)**

## Scores

| Criterion | Score |
|-----------|-------|
| 1-1: Novel data clearly described | 3 |
| 1-2: Novel/under-explored problem | 2 |
| 1-3: Novel insights/findings | 2 |
| 2-1: Scientific rigor | 1 |
| 2-2: AI methods innovative/appropriate | 2 |
| 2-3: Comprehensive analysis | 2 |
| 3-1: Domain expert co-authors | 2 |
| 3-2: Discusses AI challenges in domain | 2 |
| 3-3: Key contributions to domain | 2 |
| 4-1: Limitations & Ethics section | 1 |
| 4-2: (Second ethics criterion) | 1 |

## Strengths
- S1: Important and practical problem; clinically meaningful and timely
- S2: Strong dataset contribution; the triplet design fills a major gap in medical NLP
- S3: Provenance emphasis is appropriate for high-stakes clinical use

## Weaknesses
- **W1: Full-document vs. RAG comparison is uninterpretable.** Average evidence length is 134,180 characters (~30K+ tokens). Many models have 8K/32K context limits. What does "full-document" actually mean? Requests: exact preprocessing/inference pipeline, truncation/coverage statistics for all 3,116 samples, length-controlled re-analysis.
- **W2: Accrual gains (25-246%) are likely overstated.** The scalar multiplication approach doesn't account for trial-specific interactions. Requests: reframe as hypothesis-generating projections, add uncertainty bounds/sensitivity analysis, validate on retrospective data if possible.
- **W3: Representative examples C2 and C6 have logical inconsistencies.** C2 tightens ECOG (<=2 -> <=1) yet reports +233% gain. C6's trial already uses ECOG <=1, making the change non-actionable, yet +246% gain is propagated. Requests: separate patient-level matching from trial-level accrual metrics, enforce directionality checks, revise/remove these examples.

## Explicit Upgrade Conditions
> "I am open to upgrading my recommendation at rebuttal if the authors (1) clarify the exact full-document preprocessing pipeline with truncation/coverage statistics, (2) correct the accrual-impact framing by separating patient-level matching from trial-level enrollment, and (3) revise or remove logically inconsistent representative examples (e.g., C2/C6) with a corrected analysis."
